FDA Drafts Guidance Telling Drug Makers How to Answer Form 483 Inspection Findings

The US Food and Drug Administration has issued draft guidance telling drug manufacturers how to respond to Form 483 inspectional observations issued at the end of a current good manufacturing practice (CGMP) inspection, including a recommendation to reply within 15 business days, according to the FDA's guidance page, read in its March 6 version via the Internet Archive. Regulatory Focus, published by RAPS, reported the draft on March 6.

The guidance, "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection," was issued jointly by the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Veterinary Medicine and the Office of Inspections and Investigations. It applies to foreign and domestic human and animal drug manufacturing establishments, and the draft document says it is also intended for combination product makers where CDER or CBER is the lead center. It is a draft, labelled "Not for implementation," under docket FDA-2025-D-1504.

RAPS reported that the FDA had not previously provided specific guidelines on responding to a Form 483 after a drug GMP inspection. Device makers are not covered: the draft notes in a footnote that the Center for Devices and Radiological Health already has a corollary guidance on nonbinding feedback after certain device inspections, from April 2020.

A 15-business-day window

A Form 483 lists observations made by FDA investigators during an inspection but "does not represent the Agency's final findings" on compliance, the draft says. Responding is voluntary. The FDA recommends that establishments that choose to respond do so within 15 business days of the form being issued, in a single response covering all observations rather than several responses to individual items.

If a response arrives within that window, the FDA generally plans to review it in detail before deciding on further action. The draft says the agency will not ordinarily delay regulatory action, such as a warning letter, to review a response received after 15 business days. For complex observations that cannot be fully addressed in that time, the FDA recommends submitting a corrective and preventive action (CAPA) plan and a proposed timeline within the 15 days.

What a response should contain

The draft asks for a table of contents, the identity of the establishment and its FDA Establishment Identifier, a copy of the Form 483, the identity of whoever prepared the response and a signature from a member of executive management with authority to commit resources. It also asks for an executive summary of remediation, a patient- and product-focused risk assessment of each observation, and investigation reports that identify root causes and any systemic issues.

Correspondence should be in English, with originals and translator details supplied for translated documents. The draft says documents in another language without an English translation generally will not be included in the agency's review.

The FDA also warns against narrow investigations. In one example in the draft, an observation about one improperly cleaned piece of equipment should prompt a review of all equipment cleaned with the same deficient procedure and all drugs made with it. Addressing the "most obvious causal factor is often not sufficient," the document says.

According to RAPS, the Federal Register announcement said the agency has received inadequate responses that include missing or irrelevant data, too much data or a failure to address root causes. The draft also tells firms that disagree with an observation on scientific or technical grounds to set out the contested facts and supporting data in the response, and points them to the FDA Ombudsman for further concerns.

RAPS reported that comments are being accepted at regulations.gov under the docket number through May 6.